Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Factor VIII inhibitor bypassing fraction
Baxter Healthcare Pty Ltd
Medicine Registered
FEIBA-NF (Factor VIII inhibitor bypassing fraction) Consumer Medicine Information _ _ FEIBA-NF CMI 121004 Page 1 of 4 Baxter FEIBA-NF WHAT IS IN THIS LEAFLET? This leaflet answers some common questions about the FEIBA-NF. It does not contain all of the available information. All medicines have risks and benefits. Your doctor has weighed the risks against the benefits of using FEIBA-NF for you. It does not take the place of talking to your doctor or pharmacist. If you have any concerns about having this medicine, ask your doctor or pharmacist. WHAT FEIBA-NF IS USED FOR? FEIBA-NF is used for the treatment of bleeding in haemophilia A patients who have developed inhibitors (antibodies) against coagulation Factor VIII (FVIII), and in haemophilia B patients with inhibitors against factor IX (FIX). It is used in situations where another product (recombinant factor VIIa) is unsuitable. HOW DOES FEIBA-NF WORK? Under normal physiological conditions, FVIII and FIX are essential for blood clotting and therefore the control of bleeding episodes. Individuals with haemophilia A have decreased FVIII in their blood circulation, and individuals with haemophilia B have decreased levels of FIX. These deficiencies may lead to heavy bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. FVIII and FIX replacement therapy have been successfully used for the treatment of haemophilia A and haemophilia B. However, some haemophilia A and haemophilia B patients develop antibodies against FVIII and FIX, respectively, in the course of their treatment, leading to replacement therapy becoming ineffective. FEIBA-NF, can bypass the effects of these antibodies, thus normalizing the blood clotting process. FEIBA-NF is Read the complete document
FEIBA-NF (Factor VIII inhibitor bypassing fraction) Product Information _ _ FEIBA-NF PI 130716 Page 1 of 12 Baxter FEIBA-NF NAME OF THE MEDICINE Factor VIII inhibitor bypassing fraction. DESCRIPTION FEIBA-NF is a sterile lyophilized powder containing a complex of coagulation factors. It is intended for intravenous administration after reconstitution. The potency of FEIBA-NF is expressed in arbitrary units. One Unit of activity is defined as that amount of FEIBA-NF that shortens the activated partial thromboplastin time (aPTT) of a high titre Factor VIII inhibitor reference plasma to 50% of the blank value. FEIBA-NF contains Factors II, IX and X, mainly non-activated, and Factor VII mainly in the activated form. In addition, 1-6 units of Factor VIII coagulation antigen (FVIII C:Ag) per mL are present. FEIBA-NF is prepared from pooled human plasma. During manufacture, the product is subjected to two dedicated viral inactivation steps – vapour heat treatment and nanofiltration. FEIBA-NF is available in two strengths: 50 FEIBA-units/mL (2500 U and 1000 U) and 25 FEIBA-units /mL (500 U). The composition of the two strengths after reconstitution is given in the following table: TABLE 1: FEIBA-NF COMPOSITION _ _ _ACTIVE INGREDIENT _ Factor VIII inhibitor bypassing fraction As contained in plasma protein 500 U 200 – 600 mg 1000 U 400 – 1200 mg 2500 U 1000 – 3000 mg _ _ _INACTIVE INGREDIENT: _ Sodium Chloride Sodium Citrate 160 mg 80 mg 160 mg 80 mg 400 mg 200 mg Sterilised Water for Injection (sWFI) 20.0 mL 20.0mL 50.0 mL FEIBA-NF (Factor VIII inhibitor bypassing fraction) Product Information _ _ FEIBA-NF Read the complete document